Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PLUR Pluri Inc
1.070-0.065-5.73%
Close
02/03 16:00 ET
1.0700.0000.00%
Post Mkt Price 02/03 16:59 ET
High
1.140
Open
1.100
Turnover
13.61K
Low
1.070
Pre Close
1.135
Volume
12.12K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
12 Health Care Stocks Moving In Friday's After-Market Session
GainersNymox Pharmaceutical (NASDAQ:NYMX) shares moved upwards by 24.7% to $0.54 during Friday's after-market session. The company's market cap stands at $48.8 million. First Wave BioPharma (NASDAQ:FW
Contrasting Talaris Therapeutics (NASDAQ:TALS) & Pluri (NASDAQ:PLUR)
Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Pluri (NASDAQ:PLUR – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on t
Plurilock Receives Sale Orders for Technology Division's Flagship Cybersecurity Platform
02:16 PM EST, 01/05/2023 (MT Newswires) -- Plurilock Security Inc. (PLUR.V), an identity-centric cybersecurity solutions provider for workforces, says its Technology Division has received sale orders
Pluri CEO Issues Letter to Shareholders on Progress in 2022
Pluri Prices Private Placement
Pluri Prices $8.2 M Private-Placement Offerings At-The-Market Under Nasdaq Rules >PLUR
Pluri Prices $8.2M Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company, announced today that it has signed securities purchase agreements with domestic and non-U.S. investor
Pluri (NASDAQ:PLUR) Trading Up 4.7%
Shares of Pluri Inc. (NASDAQ:PLUR – Get Rating) were up 4.7% during trading on Thursday . The company traded as high as $0.92 and last traded at $0.91. Approximately 111,089 shares were traded durin
Pluri (NASDAQ:PLUR) Shares Up 4.7%
Pluri Inc. (NASDAQ:PLUR – Get Rating)'s share price shot up 4.7% on Thursday . The stock traded as high as $0.92 and last traded at $0.91. 111,089 shares were traded during trading, a decline of 76%
Pluri to Present and Participate in Upcoming Conferences
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the "Company")(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, t
Company Overview
More
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
CEO： Mr. Yaky Yanay
Market： NASDAQ
Listing Date： 12/10/2007
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet